Edition:
United States

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

67.52USD
22 Aug 2019
Change (% chg)

$-0.02 (-0.03%)
Prev Close
$67.54
Open
$67.79
Day's High
$68.00
Day's Low
$66.82
Volume
1,695,877
Avg. Vol
2,162,398
52-wk High
$98.69
52-wk Low
$62.68

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.10 29.89 32.67
EPS (TTM): 4.09 -- --
ROI: 11.74 14.89 14.48
ROE: 113.57 16.01 15.78

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

Aug 16 2019

UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

Aug 16 AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

Aug 16 2019

FDA approves AbbVie's new rheumatoid arthritis drug

Aug 16 The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.

Aug 16 2019

Judge certifies Niaspan 'pay-for-delay' class action against AbbVie, Teva

A federal judge on Wednesday certified a class of drug purchasers suing AbbVie Inc and Teva Pharmaceutical Industries Ltd over an alleged anticompetitive agreement that delayed the release of a generic version of the cholesterol drug Niaspan.

Aug 14 2019

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc , which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Aug 06 2019

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Aug 6 Allergan Plc, which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Aug 06 2019

UPDATE 4-Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

July 30 Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

Jul 30 2019

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

Jul 26 2019

UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane

July 26 AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

Jul 26 2019

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc .

Jul 26 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates